@article {1511501, title = {Combination of Intravenous Methotrexate and Methylprednisolone Therapy in the Treatment of Severe Ocular Inflammatory Diseases}, journal = {Ocul Immunol Inflamm}, year = {2020}, month = {2020 May 14}, pages = {1-5}, abstract = {: To evaluate the efficacy of intravenous methotrexate and methylprednisolone in severe, sight-threatening ocular inflammatory conditions.: This was a retrospective observational case series. Patients who had received intravenous methotrexate for ocular inflammation with at least 24\ months of follow-up were included in the study.: Ten patients (20 eyes) were included in this study. Mean age of the patients was 47.2\ {\textpm}\ 17.7 (range:19-74). At 1-month follow-up visit, nine patients showed improvement and one patient failed treatment. At 12-month follow-up visit, all patients were in remission. Two patients were only on intravenous methotrexate infusions. At twenty-four-month follow-up visit, only one patient, in remission, was on intravenous methotrexate therapy. Leukopenia was the only adverse effect observed.: Intravenous methotrexate and methylprednisolone infusions can be an effective method of treatment in patients with severe, sight-threatening ocular inflammatory conditions.}, issn = {1744-5078}, doi = {10.1080/09273948.2020.1746356}, author = {Maleki, Arash and Ueberroth, Jordan A and Walsh, Marisa and Foster, Frances and Chang, Peter Y and Anesi, Stephen D and Foster, Charles Stephen} }